Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Precision Medicine Clinical Trials

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 9 of 9
Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study
David M Hyman
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Howard Burris
Sarah Cannon Research Institute, Nashville, TN, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors
Jayesh Desai
Royal Melbourne Hospital, Melbourne, Australia
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma
Ryan J Sullivan
Harvard Medical School/MGH, Boston, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Alex A. Adjei
Mayo Clinic, Rochester, MN, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study
Birgit Geoerger
Inst. Gustave Roussy, Villejuif, France
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Yael P Mosse
Children's Hospital of Philadelphia, Philadelphia, PA, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Final results of the HERACLES trial in HER2-amplified colorectal cancer
Silvia Marsoni
Grande Ospedale Metropolitano Niguarda, Milano, Italy
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Rodrigo Dienstmann
Vall dĀ“Hebron Inst. of Oncology, Barcelona, Spain
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 9 of 9